Michael Shaffer, MD
Family Medicine · Marysville, OHNPI 1811154909
Payments from drug & device makers
Across 121 payments — averaging $17.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$411
- Novo Nordisk$362
- Lilly USA, LLC$208
- Amgen$152
- Abbott$129
- Pfizer$118
- plus $738 from 23 others
What the payments were for
- Food & beverage$2,10499%
- Education$141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 27 | $411 |
| Novo Nordisk | 20 | $362 |
| Lilly USA, LLC | 13 | $208 |
| Amgen | 9 | $152 |
| Abbott | 6 | $129 |
| Pfizer | 6 | $118 |
| Exact Sciences | 4 | $77 |
| GSK | 4 | $72 |
| Merck | 4 | $72 |
| AstraZeneca | 4 | $65 |
| Johnson & Johnson | 3 | $62 |
| Sanofi-aventis U.S. LLC | 2 | $44 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $42 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $35 |
| Inspire Medical Systems, Inc. | 1 | $26 |
| Dexcom, Inc. | 1 | $25 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Corcept Therapeutics | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Mannkind Corporation | 1 | $19 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
| Tactile Systems Technology Inc | 1 | $18 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $16 |
| Boehringer Ingelheim | 1 | $15 |
| Novartis | 1 | $14 |
| Noven Therapeutics, LLC | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
How this compares
$2,118 in reported general payments places this provider in the 75th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 131 | $153,191 |
| EliquisApixaban | 72 | $63,881 |
| OzempicSemaglutide | 52 | $59,408 |
| JardianceEmpagliflozin | 61 | $52,723 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 51 | $41,626 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $22,043 |
| TrulicityDulaglutide | 14 | $16,646 |
| Tresiba Flextouch U-200Insulin Degludec | 18 | $14,351 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 30 | $9,439 |
| JanuviaSitagliptin Phosphate | 14 | $7,580 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $7,356 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 13 | $6,255 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $5,128 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 18 | $3,316 |
| Atorvastatin Calcium | 413 | $3,182 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $208 | $169,837145 claims |
| PfizerEliquis, Abrysvo | $118 | $73,320102 claims |
| Novo NordiskOzempic | $362 | $59,40852 claims |
| Boehringer IngelheimJardiance | $15 | $52,72361 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $44 | $41,62651 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Shingrix | $72 | $36,93167 claims |
| MerckJanuvia | $72 | $7,58014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Marysville
- Michael ButcherCincinnati$18.3M
- William RandallKettering$7.5M
- Paul NugentCincinnati$4.9M
- Steve ChoiDayton$4.8M
- Martin SchearDayton$2.2M
- Rajesh DavitCincinnati$2M
- Kwabena OtengSpringdale$2M
- Blaise GattoMoraine$1.8M
- Cathy GreiweColumbus$1.4M
- Brian BeesleyColumbus$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.